Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 1;29(9):2634-2636.
doi: 10.1016/j.ymthe.2021.08.015.

CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease

Liliane Tenenbaum  1
Affiliations
Comment

CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease

Liliane Tenenbaum. Mol Ther. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Voutilainen M.H., Arumäe U., Airavaara M., Saarma M. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson’s disease. FEBS Lett. 2015;589(24 Pt A):3739–3748. - PubMed
    1. Albert K., Raymundo D.P., Panhelainen A., Eesmaa A., Shvachiy L., Araújo G.R., Chmielarz P., Yan X., Singh A., Cordeiro Y. Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo. Mol. Ther. 2021;29:2821–2840. - PMC - PubMed
    1. Carlsson A. A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture. Biosci. Rep. 2001;21:691–710. - PubMed
    1. Limousin P., Pollak P., Benazzouz A., Hoffmann D., Le Bas J.F., Broussolle E., Perret J.E., Benabid A.L. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345:91–95. - PubMed
    1. Manfredsson F.P., Polinski N.K., Subramanian T., Boulis N., Wakeman D.R., Mandel R.J. The Future of GDNF in Parkinson’s Disease. Front. Aging Neurosci. 2020;12:593572. - PMC - PubMed

Publication types